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Amyloid b oligomers (Abo) are the main toxic species in Alzheimer's disease, which have been targeted for
single drug treatment with very little success. In this work we report a new approach for identifying
functional Abo binding compounds. A tailored library of 971 fluorine containing compounds was
selected by a computational method, developed to generate molecular diversity. These compounds
were screened for Abo binding by a combined 19F and STD NMR technique. Six hits were evaluated in
three parallel biochemical and functional assays. Two compounds disrupted Abo binding to its receptor
PrPC in HEK293 cells. They reduced the pFyn levels triggered by Abo treatment in neuroprogenitor cells
derived from human induced pluripotent stem cells (hiPSC). Inhibitory effects on pTau production in
cortical neurons derived from hiPSC were also observed. These drug-like compounds connect three of
the pillars in Alzheimer's disease pathology, i.e. prion, Ab and Tau, affecting three different pathways
through specific binding to Abo and are, indeed, promising candidates for further development.Introduction
Dementia is a family of age-related, incurable, and debilitating
conditions which are characterised by a serious loss of cognitive
ability beyond normal ageing that affects both men and
women.1 Currently, 50 million people are suffering from
dementia globally and this number is expected to increase toeffield, Brookhill, Sheffield S3 7HF, UK.
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85over 152 million by 2050.2 The global healthcare cost of
dementia in 2018 escalated to $1 trillion dollars and is expected
to double to $2 trillion by 2030. This hampers social and
economic development and overwhelms health and social
services, including the long-term care service.2
Alzheimer's disease (AD) accounts for about 80% of all
dementia cases. The onset of AD normally occurs in the later
stages of human life (60–70 years old) and is triggered by many
different pathological and environmental factors. The accu-
mulations of the protein fragment b-amyloid (called b-amyloid
plaques) deposited outside neurons, and an abnormal form of
the protein tau (called tau tangles) accumulated inside neurons
are two of several pathological changes associated with AD.3 b-
amyloid plaques are believed to contribute to cell death by
interfering with neuron-to-neuron communication at
synapses,4–9 while tau tangles block the transport of nutrients
and other essential molecules inside neurons.10,11 Most AD
cases are of sporadic origin and the onset of cognitive behav-
ioural impairment occurs well before clinical symptoms are
seen.12
Over the past three decades, no single curative treatment for
AD has been developed although some reached advanced clin-
ical trial stages. For example, solanezumab, a monoclonal
antibody targeting the central epitope of monomeric amyloid-b,© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article OnlineKLVFFAED, with picomolar affinity, was developed by Eli Lilly in
2002.13–15 Solanezumab entered Phase II clinical trials in 2006,
and was withdrawn from development in 2018 aer over 15
years of studies and a billion dollar investment.16 The latest
casualty is aducanumab from Biogen which is another mono-
clonal antibody targeting the aggregated forms of Ab amyloid.
Biogen halted development of the drug in March 2019 aer
preliminary data from two Phase III trials suggested it would
not meet the primary endpoint. However, in October 2019 the
company announced their intention to seek regulatory
approval, following a reanalysis of the data.17
There are many reasons for such a high failure rate in AD
drug discovery and development.18 The most pressing one is
that the vast majority of current therapeutic approaches as
demonstrated above only focus on a single target (mainly
around amyloid beta) which alone is insufficient to cure AD,
a complex disease with multiple causes.19 While amyloid beta
is still a viable and clinically validated anti-oligomeropathy
drug target, we believe that looking beyond just amyloid
binding, i.e. the downstream effects of Ab rather than on its
accumulation and aggregation alone, especially how the
binding affects its binding partners and other related signal-
ling pathways, may be advantageous in improving the success
rate of drug discovery for AD and produce urgently needed
therapies.
It is commonly accepted that pathogenic amyloid beta (Ab or
Abeta), Ab1-42, is the main component of the amyloid plaques
found in the brains of Alzheimer patients.4,16 This peptide is the
product of proteolytic cleavage of the amyloid precursor protein
(APP) by b-secretase and g-secretase.20,21 Monomeric Ab1-42 can
aggregate to form exible soluble oligomers which may exist in
several forms from small oligomers to brils.8 The formation of
oligomeric species precedes the formation of amyloid plaques
and the presence of protobrils and oligomers correlates well
with the neurotoxicity showing that oligomers have played
a critical role in the pathogenesis and progression of AD (oli-
gomeropathy).22–24 In addition, the misfolded oligomers (known
as “seeds”) can induce Ab molecules to also take the misfolded
oligomeric form, leading to a chain reaction akin to a ‘prion’
infection.25–27 The other key protein, tau, which is also involved
in AD forms ‘prion-like’misfolded oligomers (Tauopathy).28 It is
also believed that there is a connection between oligomeropathy
and tauopathy, i.e. misfolded Ab oligomers can induce tau to
misfold.10,23
In addition, several receptors for Ab1-42 oligomers (Abo will
be used throughout this paper unless otherwise stated) at
synapses were discovered. Notably, the cellular prion protein
(PrPC) has high affinity for Abo.29 PrPC, a glyco-
sylphosphatidylinositol (GPI)-anchored protein of 231 amino
acids encoded by the PrnP gene located on chromosome 20 in
humans, is widely expressed in the central nervous system
during early development, and in adult neurons and glial cells.
In the adult brain, maximal PrnP mRNA expression is observed
in the neocortex and cerebellum. Although its involvement in
transmissible spongiform encephalopathies is well known,
PrPC is thought to be related to several normal and abnormal
physiological processes.11 In AD, conditional deletion of the© 2021 The Author(s). Published by the Royal Society of ChemistryPrnP gene by anticancer drug, tamoxifen,30,31 rescued synapse
loss in APP/PS1 mice models. The interaction between PrPC and
Abo appears to be involved in maintaining cognitive impair-
ment in later stages of AD and endogenous or, synthetic ligands
of PrPC interrupt Abo mediated signalling and prevent neuro-
toxicity in neurons.12,29,32 Evidence also shows that PrPC deletion
inuences tau hyperphosphorylation because Fyn has been
linked to somatodendritic accumulation of Tau. Therefore,
cellular prion protein, PrPC, plays a vital role in the central
dogma of AD aetiology connecting oligomeropathy with Tau-
opathy. Therefore, Ab oligomers, PrPC, Fyn and Tau could all
become potential polypharmacological drug discovery targets
for AD.33
Here, we present a combined computational, biophysical,
biochemical, and cellular effort in developing novel drug
discovery approaches against AD. We developed a virtual
screening strategy for identifying putative Abo binders. We
identied compounds reported as inhibitors for Ab in the
public domain and in the literature and used these compounds
to search a library of uorine-containing compounds using
a fragment-based approach. Sub-libraries of compounds sug-
gested from virtual screening were examined in a 19F NMR assay
to identify compounds that bind to Abo. The hit compounds
were further tested in a number orthogonal NMR based assays
to conrm their specic binding to Abo.
Furthermore, we have identied several promising chem-
ical scaffolds and tested them in cellular assays to validate
their bindings and biological activities. We have developed
a cellular-based Abo–PrPC binding assay using HEK293 cell
line. The selected compounds were also tested in more disease
relevant models using induced human pluripotent stem cells
(ihPSC) for their abilities in inhibiting hyperphosphorylations
of Fyn and Tau. Together with an enzymatic BACE assay, these
compounds were shown to specically bind to Abo, disrupt the




Designing uorine-containing fragment library. The design
of a compound library targeting Abo was inspired by the work
reported by Joshi et al.34 who used a computational fragment-
based approach to produce small molecule libraries targeting
intrinsically disordered proteins from known anti-amyloidal
compounds. In order to generate a more specic and focused
library for subsequent binding studies against Abo using 19F
NMR, a computational pipeline was developed as illustrated
(Fig. 1a) and described in detail in the Methods section.
We identied 151 known Abo inhibitors from the literature
and public databases (ESI Table 1†). These seed compounds
were fragmented and then these fragments (aer ltering very
simple fragments like phenyl rings) were used to perform
a substructure search on a tailored chemical library consisting
of 7220 uorine-containing compounds. This library was
a subset of a larger library of 73 848 compounds constructed
from public databases such as ChEMBL, PubChem, Drugbank,Chem. Sci., 2021, 12, 3768–3785 | 3769
Fig. 1 Computational design of fluorine containing anti-
oligomeropathy compound library. (a) Flowchart for database
construction and screening cascade. (b) A schematic illustration of
computational fragment-based approach from a known Ab binder
CHEMBL489792.

































































































View Article Onlineand ZINC. The sub-library consists of compounds containing
at least one uorine atom and the compounds were available
in Lilly's internal inventory (to allow for rapid procurement ofTable 1 19F NMR screening data for 27 hit compounds
3770 | Chem. Sci., 2021, 12, 3768–3785the compounds). This uorine subset was specically selected
to allow 19F NMR screening to be employed.35
The initial substructure search against the F-containing
chemical library yielded 4142 initial hits from which 2000
diverse compounds were selected. Further assessment on their
predicted solubility resulted in 971 compounds which were
taken forward into the 19F NMR screening (ESI Table 2†). The
design cascade can be illustrated using a known Ab binder
CHEMBL489792 as an example (Fig. 1b). CHEMBL489792 is an
aminostyrybenzofuran derivative which was reported to be
a potent inhibitor for Ab bril formation with IC50 of 0.07 mM
in thioavin T (ThT) assay.36 Fragments were generated from
this compound and these fragments were screened against the
complied uorine-containing database subset resulting in
compounds that share the identied fragment substructures.
Hit expansion by similarity search. A similarity search
against the main database of 73 848 compounds was applied to
the 8 hits from the initial 19F NMR screening in order to
produce more analogues in the hit expansion exercise. 36
uorine and non-uorine containing structural analogues were
selected computationally (ESI Table 4†). These compounds were
screened in a competition assay using the 19F NMR technique
employed in the primary screening. This round of hit expansion
exercise yielded 6 more hit compounds (Table 2). All 14 hits
were then further validated and characterised by STD NMR to
give 9 conrmed hits of which 6 were progressed to biological
validation.NMR screening and characterisation of binding
Ab oligomer preparation and characterisation. The Ab1-42
oligomers (abbreviated as Abo unless otherwise stated) used in© 2021 The Author(s). Published by the Royal Society of Chemistry
Table 2 Six new hit compounds from the hit expansion competition assay
Entry
Library










1 1009 CHEMBL1673279 PBCHM45210798 153.86 37.44 4.11 8.74
2 1048 PBCHM3049683 PBCHM57223647 167.81 37.10 4.52 2.96
3 ZINC00159801 130.88 37.44 3.50 2.32
4 ZINC00057047 75.89 37.48 2.02 1.32
5 1055 PBCHM120765 CHEMBL448523 298.75 36.90 8.10 5.91
6 ZINC00120199 159.16 36.94 4.31 1.63
Fig. 2 Ab1-42 oligomer preparation and validation of NMR protocols.
(a) size exclusion profile of the preparation over 1 hour (b) size of the
oligomers analysed by dynamic light scattering (DLS) technique; (c)
Section of 1H NMR spectra of 50 mM bexarotene in the presence (red)
and absence (blue) of 1 mM of Abo. The reduction of peak height upon
the addition of the Ab1-42 oligomer preparation indicates an interaction
between bexarotene and the oligomer preparation; (d) section of 19F
NMR spectra of 50 mM flurbiprofen in the presence (blue) and absence

































































































View Article OnlineNMR screening were prepared from synthetic Ab1-42 polypeptide
using a protocol previously described.37,38 Briey, dry lms were
prepared from hexauoro-2-propanol (HFIP) solution of
synthetic Ab1-42 polypeptide which were then hydrated with
Neurobasal medium and desalted using a HiTrap column. The
fractions collected with known Ab1-42 monomer concentrations
were allowed to oligomerize for 1 hour at room temperature,
followed by centrifugation. The supernatant containing Abo
were collected and characterised by dynamic light scattering
(DLS) technique. The size and distribution of amyloid beta (Ab1-
42)-derived diffusible ligand (ADDL) preparations were assessed
(Fig. 2a). A typical prole of the Abo preparation consisted of
three major populations of oligomers with hydrodynamic radii
between 10 nm and 100 nm (Fig. 2b). This size distribution
prole is broadly in line with the Abo isolated from human
brain tissues of AD patients.39 Despite the fact the formation of
oligomers and brils are dynamic in nature, the oligomers
prepared using this protocol showed about 70% oligomer
population as smaller species with an average molecular weight
of 146 kD. Given that the molecular weight for Ab1-42 monomer
is at around 4.5 kD, Most oligomers should exist as 30-mers or
below which falls in the range of 10–50-mers soluble Abo that
exist natively in the brain of AD patients.40 The Abo prepared
maintains good solubility in buffers used in NMR experiment as
the oligomers up to 1600-mers were reported in a soluble state.41
Due to the large quantity and high purity of Abo required for
NMR screening, it is not viable and ethical to extract them from
human AD brain tissue, we adapted a protocol to produce Abo
from synthetic Ab1-42 monomers that resemble the native Abo
population as much as possible despite of heterogeneity of the© 2021 The Author(s). Published by the Royal Society of Chemistrydistribution. The Abo of this prole were used for all NMR
experiments in this paper unless otherwise stated.
Design and validation of NMR screening techniques. To
assess the suitability of the Abo prepared for the NMR screening
experiments and optimize the assay conditions, bexarotene was
selected to validate the binding interaction between Ab-oligo-
mers and small molecules. Bexarotene is a clinically proven
anticancer treatment for cutaneous T cell lymphoma (CTCL)(red) of 1 mM of bovine serum albumin (BSA).
Chem. Sci., 2021, 12, 3768–3785 | 3771
Fig. 3 19F CPMGNMR screening. (a) Section 19F CPMGNMR spectra of
sub-library 1045 containing 50 mM of compound ZINC02382246
(57.6 ppm), PBCHM57487213 (62.3 ppm) and PBCHM5157960
(75.5 ppm) in the presence (red) and absence (blue) of 1 mM
(concentration as monomer) Abo; (b) section 19F CPMG NMR spectra
of PBCHM57487213 (62.3 ppm) in the presence (red) and absence
(blue) of 1 mM (concentration as monomer) Abo in the individual 19F
NMR confirmation run; (c) section 19F CPMG NMR spectra of
PBCHM57487213 (62.3 ppm) in the presence (red) and absence
(blue) of 1 mM (concentration as monomer) scrambled peptide; (d)
section 19F CPMG NMR spectra of PBCHM13530069 (62.3 ppm) in
the presence (red) and absence (blue) of 1 mM (concentration as
monomer) scrambled peptide; (e) 19F CPMG NMR spectra of 50 mM of
seed compound PBCHM57487213 binding to 1 mM (concentration as
monomer) Abo in competition with 50 mM of analogue
PBCHM3738144 in the presence (red) and absence (blue) of the
analogue compound in the hit expansion experiment; (f) 19F CPMG
NMR spectra of 50 mMof seed compoundCHEMBL1673279 binding to
1 mM (concentration as monomer) Abo in competition with 50 mM of
analogue PBCHM45210798 in the presence (red) and absence the
analogue compound in the hit expansion experiment.

































































































View Article Onlineand off-label treatment for lung and breast cancers.42–44 It was
reported to compete with cholesterol in Ab binding and inhibit
the amyloid aggregation.45–48 Because there was no uorinated
bexarotene available, 1H-CPGM NMR experiments were used in
the binding assay. The overlay of the spectra of bexarotene in
the presence and absence of Abo is presented in Fig. 2c. The
reduction of peak height in the presence of the oligomers in this
experiment conrms the binding between bexarotene and Abo
prepared. Bexarotene was therefore selected as a positive
control in all relevant NMR experiments unless otherwise
stated.
The same protocol was applied to a model system to test if
the experimental conditions for bexarotene and Abo were
applicable for 19F NMR screening of virtual hits from computer
modelling. A model system consisting of bovine serum albumin
(BSA) and its known uorine-containing binding ligand, ur-
biprofen, was constructed. The urbiprofen is a nonsteroidal
anti-inammatory agent (NSAIA) with antipyretic and analgesic
activity. It is an analogue of ibuprofen and >99% of it was bound
to albumin aer administration.49,50 Suppression of the 19F
signals (Fig. 2d) of urbiprofen upon BSA binding clearly
demonstrated that the 19F NMR protocol can be used as
a primary screening tool for virtual hits against Abo prepared.
19F CPMG NMR is becoming an increasingly popular tool in
the eld of drug screening51 because each 19F atom, which is
a 100% naturally abundant uorine NMR-visible isotope, is
absent in biomolecules such as proteins, F-containing
compounds generates a unique chemical shi in the spec-
trum which is oen simple with no erroneous background
noise and interference from other signals, and hence can be
easily identied.52 Moreover the uorine nucleus is very sensi-
tive to changes in the chemical environment, and can be a very
sensitive probe even for the weakest binders. In addition, the
large chemical shi range and the strong chemical shi
anisotropy make it very simple to measure mixtures of up to 30
fragments in a single sample. When a small molecule is bound
to a large protein, the signal intensity of the binding ligand is
signicantly attenuated by Carr–Purcell–Meiboom–Gill (CPMG)
or spin-lock pulse due to interaction with protein. In this
experiment, the 19F NMR methodology provides a sensitive tool
not only for probing compound binding to Abo, but also for
rapidly deconvoluting library members from the mixture due to
the unique shi of each library member in 19F NMR spectra.53
Therefore, the throughput of the NMR screening can be
increased and the amount of Abo required for the screening
reduced. The only disadvantage of this technique is that
compounds tested (in direct binding measurement at least)
need to have at least one uorine atom.
Primary screening by 19F-CPMG NMR. In this work,
a collection of 971 uorine-containing hits from the virtual
screen were sourced for 19F CPMG NMR screening from Lilly's
internal compound collection. These compounds were initially
tested for their solubility and stability in the media which was
used for the Ab oligomer preparation in the method validation
section. Compounds that were not suitable were discarded and
individual 19F CPMG NMR spectrum for each of the remaining
614 compounds were acquired and stored for compound3772 | Chem. Sci., 2021, 12, 3768–3785grouping in sub-library design and for hit identication. These
614 compounds were then organised into 91 sub-libraries, each
containing 6 or 7 compounds. The sub-libraries were designed
using a modied version of the NMRmix soware and based on
individual chemical shis of each compound in the 19F-CPMG
NMR spectrum. The chemical shi(s) of each compound in
the library were spread out as far as possible, yet not exceeded
a spectral width causing pulses in the sequence to deviate
signicantly from the ideal. Compounds with overlapping
chemical shis were placed in different libraries. The sub-
libraries were also designed to ensure that chemical shis
from library members are sufficiently different to allow imme-
diate assignment of any active components.© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 4 Structure of 27 hits from sub-library screening.

































































































View Article OnlineThe 19F CPMG NMR experimental protocol described above
was then used to screen compounds in 91 uorine-containing
sub-libraries in the presence and absence of Abo. An example
of sub-library screening is illustrated in Fig. 3. A section of
spectra of three compounds from the 19F CPMG NMR experi-
ment of sub-library mixture 1045 containing six compounds in
the absence (blue) and the presence (red) of Abo is shown in
Fig. 3a. It was seen that compound PBCHM57487213 showed
a noticeable reduction in the peak height.
In order to assess if any changes in peak intensity are
statistically signicant, the ratio of peak reduction/noise and %
of peak height reduction are calculated for each compound. The
ratio of peak reduction/noise represents the signicance of the
peak reduction in reference to the base-line noise. A ratio of >2
has been assigned as the cut-off for a positive hit. The larger the
ratio, the more reliable the data is. The percent peak reduction
gives an indication of the relative binding abilities of
compounds in each sub-library, therefore was used as a key
parameter for measuring binding strength.
For each compound, hit compound entry, its sub-library
number where it was tested, public ID, chemical shi, reduc-
tion in the peak height upon binding to Abo, baseline noise,
signal reduction/noise ratio as well as percent of peak height
reduction compared to the peak height in the absence of Abo
are collected, presented and analysed. The 27 compounds that
showed positive responses in the presence of Ab are shown
under 19F NMR sublibrary screening column in Table 1.
It can be seen that 27 hit compounds came from 24 sub-
libraries and displayed a spectrum of abilities in peak height
reduction. Judged by % of peak height reduction, four
compounds (Table 1, entries 4, 18, 23 and 26) produced over
30% reduction in peak height, hence are classied as strong
binders. 3 compounds (Table 1, entries 2, 22, and 27) reduced
peak height by over 20%, hence are classied as medium
binders. The rest of the compounds gave between 5 and 16%
reduction in peak height in the presence of Abo making them
weak binders. Although the binding ability is arbitrarily
assigned, it provides a tool for ranking the binding signicance
of the compounds. It is tempting to conclude stronger binders
generally display a bigger ratio of peak reduction/noise than
weaker binders: fraction bound will indeed be one component
of the response, but other factors may also be important, so too
much signicance should not be placed on this. The chemical
structures for all 27 hit compounds with their public IDs are
shown in Fig. 4.
To remove false positives caused by compound–compound
interactions, compounds which were active within the mixture
screen were re-tested via the 19F CPMG NMR experiment indi-
vidually under the same conditions as they were screened in the
library mixtures and a sample is shown in Fig. 3b. Using the
same criteria and cut-offs applied in the primary sub-library
screening, 24 out of 27 compounds showed reductions in the
peak height in the presence of Abo in the individual binding
experiments, hence were deemed to be conrmed hit binders
(under 19F NMR individual experiment column Table 1). It is
interesting to observe that the binding of most compounds
(Table 1, entries 1, 4, 10, 13, 14, 15, 21, 24 and 26) to Abo in the© 2021 The Author(s). Published by the Royal Society of Chemistryindividual conrmation experiment remained at a similar level
as displayed in the primary sub-library screening. This
demonstrates that the binding of these compounds was not
affected by other compounds present in the library. Compound
entries 2, 3, 7, 8, 13, 18, 19, 20 and 27 showed noticeable
increases (>50%) in the % peak height reduction, when
compared with the reduction seen in the sublibrary screening,
showing that presence of other compounds in the sub-library
inhibits their binding to Abo. Compound entries 5, 11, 16, 17,
21, and 23 displayed signicant reduction in the % peak height
reduction when compared with the reduction seen in the sub-
library screening, showing that the presence of other
compounds in the sub-library enhances their binding to Abo.
It is worth mentioning that compound entries 10 and 11,
belong to the same sub-library (Library 1043), but behave
differently in the individual experiments. The presence of
compound entry 10 seems to enhance the binding of compoundChem. Sci., 2021, 12, 3768–3785 | 3773

































































































View Article Onlineentry 11 to Abo while the presence of compound entry 11 does
not seem to affect the binding of compound entry 10. However,
the interference of other compounds in the sub-library cannot
be completely ruled out. Compound entries 12 and 13 (Library
1045) displayed the opposite inuence of one compound to the
other when compared with compound entries 10 and 11.
Compound entries 17 and 18 (Library 1055) affected each other
signicantly when present in the sub-library mixture. The
presence of compound entry 17 signicantly inhibits the
binding of compound entry 18 to Abo in the sub-library while
the presence of compound entry 18 signicantly enhances the
binding of compound entry 17. This shows that they not only
bind to Abo individually, but also together they exhibit the
strongest effects of compound–compound interaction upon the
binding compared with the other two pairs. Three compounds
(Table 1, entries 6, 9 and 12) displayed a negligible reduction in
peak height when re-tested individually. This shows their
bindings to Abo rely on their interaction with other compounds
in the corresponding sub-libraries. It may also mean that they
are interacting with each other. Ligand–ligand interactions
cannot be ruled out either.
The number of compounds which belong to strong binders
increased from 4 to 11 and the % of peak reduction of some
compounds has even doubled (Table 1, entries 2, 8, 19, 20, 22
and 25). The number of compounds in the medium-binder
category increased by 1 and the number of weak binders
reduced by 8. 3 compounds (Table 1, entries 6, 9 and 12) became
non-binders and were removed from the hit list.
To avoid false positives arising from non-specic binding,
these 27 initial hits were also subjected to a counter screen
against a scrambled (non-amyloidal) peptide which has the
same amino acid composition and peptide chain length, but
a different primary sequence to Ab1-42. The scramble was
prepared using the same protocol as that of Abo from Ab1-42.
A counter screen of each compound against a scrambled
peptide was also carried out in individual experiments using the
same 19F CPMG NMR technique. The scrambled peptide
possesses the same composition of amino acids, but different
primary sequence as that of disease-causing Ab1-42 sequence. It
does not aggregate to form amyloid brils, therefore is oen
used as a control peptide to examine the specicity for Ab
binders. The scrambled peptide was subjected to the same
preparation protocol as that of Abo prepared from synthetic Ab1-
42 monomers. The binding between the hit compounds and the
scrambled peptide was performed using the same protocol as
the one used for Abo binding.
All 27 initial 19F NMR sub-library hits (including the 3
negative hits in the individual conrmation experiment) were
tested against the scrambled peptide and data is displayed in
the “19F NMR scrambled peptide experiment” column in Table
1. An example of spectra for compound PBCHM57487213 (Table
1, entry 13) in the absence (blue) and presence (red) of scramble
peptides are shown (Fig. 3c). No change in the peak height
reduction was observed demonstrating that it does not bind to
the scrambled peptide, hence is a specic binder for Abo. An
example of non-specic Abo binder can be seen with compound
PBCHM13530069 (Table 1, entry 2). This compound a positive3774 | Chem. Sci., 2021, 12, 3768–3785hit in the initial sub-library screening as well as the individual
conrmation 19F-CPMG NMR screening (Fig. 3d). However, it
showed signicant binding to the scramble peptide, hence is
removed from the list of compounds for further investigation.
Out of 27 compounds, 11 were identied as specic Abo
binders that have a ratio of peak height reduction/noise less
than 2 in the presence of scrambled peptide with negative or
small % of peak height reduction. Compound entries 9 and 12,
having already shown to be non-binders in the individual NMR
experiment, also displayed no binding to the scrambled
peptide. Notably, compound entry 6, also a non-binder in the
individual experiment, displayed signicant binding to the
scrambled peptide. A compound can only be classied as a hit if
they showed peak height reduction in both sub-library
screening, individual experiment, and no peak reduction in
the scrambled peptide experiment. Hence, compound entry 6
was also removed from the hit list. This leaves 8 conrmed hits
in total (Table 1, entries 3, 7, 11, 13, 14, 15, 17, 26).
From the initial 614 compound library to 8 conrmed hits,
a hit rate of 1.3% was obtained which is higher than average
random high throughput campaign hit rate (0.01% and
0.14%).54 These hits were taken forward to the hit expansion
experiment.
Screening of hit expansion analogues. Utilising a ngerprint
similarity method, 36 near neighbour analogues of the 8 F-
containing hit compounds were identied from the original
database of 73 848 compounds. These compounds are non-
proprietary, commercially available and were in stock in the
Lilly inventory.
The 36 analogues were screened against their respective
“seed/parent compounds” in a competition experiment using
19F NMR technique employed in the primary screening to
rapidly acquire data and compound deconvolution.55 A solution
was prepared containing the same concentration of the seed
compound and its corresponding analogue, and the change in
peak height of the original F-containing seed compound in the
presence of its analogue and Abo was analysed. If the original
seed compound still displayed a reduction of peak height twice
that of the noise in the presence of the structural analogue, it
was deemed that the analogue displayed specic binding to the
same location as the seed compound. In the competition
experiment between seed compound PBCHM57487213 and its
near neighbour analogue PBCHM3738144, it is clear that there
is no competition between the compounds as no peak height
reduction is observed (Fig. 3e). This indicated that the analogue
PBCHM3738144 is either a weaker binder than its seed
compound PBCHM57487213 or it binds to a different site from
where its seed compound binds and does not interrupt the
binding of the seed compound. Conversely, analogue
PBCHM45210798 clearly competes with its seed compound
CHEMBL1673279 (Fig. 3f) suggesting that this analogue binds
at the same site on Abo as its seed compound. Its binding
strength is strong enough to compete its seed compound
partially off. From the expansion competition experiment, 6 out
of 36 compounds were identied as potential binders. Their
original location, seed compound public ID, analogue public
ID, chemical structure, NMR data on competition assay (peak© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article Onlineheight reduction, noise, reduction/noise ratio, % peak height
reduction) are shown in Table 2.
Although this competition experiment would suggest
competitive binding between the analogue and the seed for the
same site on Abo it does not eliminate the potential for the
analogues to allosterically inhibit the seed compound. From
this expansion experiment, 6 further hit compounds were
identied as potential binders (Table 2) giving a total of 14 hit
compounds from the 19F CPMG NMR experiments described
above. The hit rate has increased by 13-folder, from 1.3% in the
primary screening to 17% in the hit expansion exercise. This hit
rate enhancement demonstrates the viabilities of both the
computational and NMR approaches.Fig. 5 STD NMR characteristics (a) section of an STD spectra of 200
mM ibuprofen and 2 mM of bovine serum albumin (BSA) containing
a glucose (200 mM) control. Reference spectra (grey) and on-reso-
nance spectra (black); (b) section of an STD spectra of 200 mM bex-
arotene and 2 mM (concentration asmonomer) Abo. Reference spectra
(red), on-resonance spectra (green), control (black). (c) STD NMR of
200 mM of PBCHM57487213 and 2 mM (concentration as monomer)
Abo. (d) STD NMR of 200 mM of compounds PBCHM81560982 and 2
mM (concentration as monomer) Abo. Reference (red) spectra, on-
resonance spectra (green), control (black). Color scheme on the
structure: ranges of values for %STD moiety analysis: red ¼ #5%,
yellow ¼ $10%, green ¼ >10%. (e) Dose response curve – compound
PBCHM57487213; (f) dose response curve – compound
PBCHM81560982.Characterisation of the binding using saturation transfer
difference (STD) NMR
To further validate the hit compounds obtained from the initial
19F NMR screening, a STD screen was used as an orthogonal
binding study to characterise binding affinity and identify hot
spots on the molecule that are involved in the binding.56
Saturation Transfer Difference (STD)-NMR is oen employed
during the drug discovery process as a method of binding
validation which is complementary to 19F NMR screening. STD
NMR is increasingly used as a semi-quantitative method for
epitope mapping on ligand moieties interacting with the
protein.57 An STD NMR experiment starts with the selective
irradiation of the protons of the large biomolecule, such as
a protein, using Gaussian Rf pulses. The resulting Rf saturation
is then rapidly propagated across the entire protein through
a spin diffusion effect via non-scalar magnetization transfer. If
a smaller molecule ligand binds the receptor, saturation will
also spread onto the ligand. As a result, intensity of the proton
signals on the ligand will be attenuated. Subtraction of resulting
spectrum from a reference spectrum without saturation yields
the STD spectrum containing only signals of the binding
ligand.56 STD NMR can be used to characterise weak ligand
binding (Kd  mM to mM) and map the hot spots on the ligand
that are involved in the binding to large protein molecules (MW
> 20 kDa).57 It does not require expensive stable isotopes or
radioisotope labelling and only requires small amount of
protein (nM to pM), hence is an economical method to analyse
protein–ligand interactions especially when a large quantity of
the proteinunder study is not achievable. During the experi-
ment, the small molecules are usually used in large excess (20–
1000 times excess) of the protein concentration.
The STD-NMR protocol used in the current study was veried
by using two model systems: BSA and its known small ligand
binder, Iburpofen (Fig. 5a), and Abo and bexarotene (Fig. 5b).
Examples of STD NMR spectra of two hit compounds are shown
in Fig. 5c and d.
In each of the model systems, the STD NMR experiment
produces a “difference” spectrum by subtracting two contrast-
ing “saturation” spectra. The rst NMR spectra recorded is an
off-resonance saturation (no protein saturation ‘STDoff’) spectra
where the excitation pulse is away from the protein 1H signal.
This STDoff spectra is referred to as the “reference” spectra as it© 2021 The Author(s). Published by the Royal Society of Chemistryis comparable with a standard 1H-NMR spectrum of the ligand
(Fig. 5a (grey), Fig. 5b–d (red)). The second NMR spectra is an
on-resonance saturation (selective protein proton saturation
‘STDon’) spectra where the excitation pulse is directed at
a known protein 1H signal and does not interact directly with
the added ligand. This STDon spectra displays decreases in peak
intensity for the bound ligands. This is due to the transfer of
energy from the excited protein to the ligands in closest prox-
imity via the proton network. The difference spectra (STDdiff) is
the subtraction of the STDoff spectra from the STDon (STDdiff ¼
STDoff  STDon) (Fig. 5a (black), Fig. 5b–d (green)). The STDdiff
highlights the small changes in peak height from the STDoff to
the STDon that are not identiable.
Finally, to eliminate potential ligand–ligand interactions
interfering with the experiment the same excitation pulses and
STDdiff were recorded without the presence of a protein and
referred to as a “control” (Fig. 5b–d (black)). If a response was
seen in the “control” it was believed to be due to ligand–ligand
interactions and this false positive discarded.
From the STD-NMR experiment, additional information on
the closest proximity proton functionalities ‘hot spots’ on each
of the compound moieties can be measured semi-quantitatively
from the magnitude of the STD effect. The STD effect can beChem. Sci., 2021, 12, 3768–3785 | 3775
Table 3 Summary of STD NMR data on 14 confirmed hit compounds
from 19F NMR experiments



















































































































View Article Onlinerepresented numerically as a percentage ((STDdiff integral/
STDoff integral)  100). For each of the binders, a maximum
STD effect of each moiety was calculated and mapped onto the
atoms in each compound. The level of the STD effect was then
mapped onto the atoms of each compound and colour-coded to
reect the semi quantitative nature of the technique.
The binding between BSA and ibuprofen, with non-binding
spy compound glucose present, is shown in Fig. 5a. In the
STDoff spectrum, chemical shis for glucose can be seen
between 3 and 4 ppm which are not presented in the STDdiff as
glucose is not involved in the binding (Fig. 5a). The atoms on
the ibuprofen that are involved in the binding to BSA and their
level of commitments (% difference) in the binding are labelled
and colour-coded in the STDdiff. It is clear that the carboxylic
acid group should have the strongest interactions with BSA as
BSA is the most abundant hydrophilic globular protein in blood
serum acting primarily as a carrier protein for hormones, fatty
acids, trace minerals, vitamins and iron.58 Strong interactions
between BSA and ibuprofen involve the aromatic region and
connected sidechains. This is expected because there are
hydrophobic side chains and peptide backbones in BSA which
favour hydrophobic interactions. This study complements to
the molecular interactions identied through the X-ray studies
of co-crystallisation of BSA and ibuprofen where hydrophobic
part of the molecular interacts strongly with the binding pocket
around Val349A and carboxylic acid group forms hydrogen
bonds with Tyr355A and Arg120A.59,60
In the more relevant model system, atoms involved in the
binding between Abo and bexarotene are labelled and colour-
coded in the STDdiff spectrum (STDoff Fig. 5b (red)), (STDdiff
Fig. 5b (green)) and (STDcontrol Fig. 5b (black)). As expected, Abo
are hydrophobic in nature, it is therefore not surprising to see
the interactions heavily rely on the hydrophobic part of the
molecule. The involvement of the carboxylic acid group cannot
be dened from the STD experiment although some ionic
interactions between the group and amine side chains should
play roles in driving the initial interaction or enhancing/
stabilising the interaction.
The protocols developed were applied to study the binding
between Abo and our hit compounds from the 19F NMR screen
(Fig. 5c and d). STDoff, (red), STDdiff (green) and control (black)
spectra were recorded for PBCHM57487213 and
PBCHM81560982. Atoms involved in the binding between Abo
and the ligands are labelled and color-coded in the STDdiff
spectra. Both compounds were shown to be medium to strong
binders in the sub-library screening and individual conrma-
tion 19F NMR experiments. Additionally, they were conrmed
specic binders from the scrambled peptide screening.
Although the percent peak differences are small and the
involvement of non-hydrogen atoms cannot be conrmed, the
aromatic protons are all shown to be affected upon Abo binding
just like bexarotene in this STD NMR experiment. This again
demonstrates that the p–p and hydrophobic interactions are
important in this type of molecular interactions.
The STD-NMR experiment was carried out with each of the 14
hit compounds with the addition of Abo. Of the 8 initial hit
compounds from the rst round of screening, 7 of them were3776 | Chem. Sci., 2021, 12, 3768–3785conrmed binders by STD NMR experiments (Table 3).
Compound CHEMBL1499171 showed no change of signal in the
STD NMR experiment, and was thus deemed inactive. Compared
to other hit binders, it was noted that this molecule is smaller
than the others (Fig. 4). We might speculate that this smaller
fragment is either of lower affinity ormakes less contacts with the
protein, both of these would result in a weaker STD signal. There
is no direct correlation between 19F NMR signal strength and
STD-NMR signal change for any of the compounds.
Only 2 out of the 6 compounds from the hit expansion
experiment showed noticeable changes in STD-NMR signals. It
is interesting to note that none of the 3 analogues from the© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article Onlinesame seed-compound, PBCHM3049683, showed any changes in
STD signals while the parent compound itself showed a good
response. As above, it is noted that the smaller more fragment-
like molecules give weaker STD signals, which may be due to
weaker binding or less efficient contracts with the protein. This
could indicate that competition assay alone may not be the best
method used for hit identication. Other validation assays such
as STD NMR should be used together to conrm the hits. Of
course, it can also indicate that STD NMR is not the best tech-
nique to pick up small molecular weight binders. It is inter-
esting to note that hit compound CHEMBL1673279 and its
analogue PBCHM45210798 consistently showed good binding
abilities in all 19F NMR and STD NMR experiments. The same
trend is seen with hit compound PBCHM120765 and its
analogue ZINC00120199. 14 hit compounds from 19F CPMG
NMR techniques were subject to the STD lter and 9
compounds were conrmed as binders from STD NMR experi-
ments (Table 3).
Compounds PBCHM57487213 and PBCHM81560982 were
chosen for dose response studies (Fig. 5e and f). As STD NMR
experiments are performed in an excess of ligand, in order to
measure a dose–response curve, the concentration of the ligand
was kept consistent while the concentration of Abo was incre-
mentally increased. The spectra were acquired over the same
period of time and the integral of the STDdiff was measured.
Both compounds adhere to a standard response of increased
protein concentration. Initially, there is an increase in response
as the protein concentration is increased and the curve then
begins to plateau indicating the active sites of the proteins are
completely occupied and this is the maximum response for the
STD experiment. Finally, the curve began to decrease as the
ligand and protein will no longer be in fast exchange. This
decreases the response of the STD experiment. The estimated Kd
for compound PBCHM57487213 is 2 mM and compound
PBCHM81560982 is 4 mM. The dose response for other STD
NMR conrmed hits were not carried out due to the availability
of those compounds.
From the 9 potential binders identied from the 19F CPMG
and STD-NMR experiments, 6 compounds (CHEMBL1673279,
PBCHM4680099, PBCHM57487213, ZINC00120199,
PBCHM120765, and PBCHM81560982) were chosen to be taken
forward and tested in a biological assay to assess the effect of
their binding upon the interfere the binding between Abo and
PrPC, and their effects on Fyn and Tau. These compounds were
chosen due to their structural diversity, biophysical results and
availabilities.Biological and functional evaluation of selected hit
compounds
To further evaluate the compounds that we identied in the
biochemical assay, we sought to answer the following ques-
tions: (1) if Abo prepared interacts with PrPC as previously re-
ported;11,61 (2) if the Abo binders identied from NMR screening
interfere with Abo–PrPC binding in a biologically relevant
manner; (3) if so, do they have polypharmacological properties,
i.e. any effects on downstream signalling (pFYN and pTau© 2021 The Author(s). Published by the Royal Society of Chemistryactivities). In order to address these issues, different cellular
screening models were developed.
The hit Abo-binders disrupt interactions between Abo and
PrPC on HEK293 cells. First of all, a cellular model was devel-
oped to assess the binding between the Abo preparation and
PrPC on the cell surface. For this, four different human cell lines
of both neuronal and non-neuronal origins were tested. A wild
type HEK293 cell line derived from human embryonic kidney
cells which was previously reported for studying Abo–PrPC
binding.62 iCells which are human glutamatergic-enriched
cortical neurons derived from iPSC and two SH-SY5Y cell lines
which were sub-cloned from a bone marrow biopsy derived line
expressing neuron-like characteristics.
We examined the level of PRNP and other Alzheimer's
disease related genes in each cell line, including FYN, NMDA
receptor genes (GRIN1, GRIN2A, GRIN2B), mGluR5(GRM5),
NACE1 and Tau producing gene (MAPT) (Fig. 6a). We found that
iCells showed the greatest expression of all examined genes
while SH-SY5Y cells contain the least relevant genes, PRNP gene
in particular. However, the wild type HEK293 cell line was
selected for studying Abo and PrPC binding because it had
moderate expression of the studied genes and it is also a robust
cell line, easy to maintain at low cost, and amenable for high
throughput screening. The expression of PrPC protein in the
HEK293 cell line is visualised by staining against anti-PrPC
antibody 8H4 (Fig. 6b) conrmed and quantied by ow
cytometry (Fig. 6c).
With the HEK293 cell line being selected as a cellular model
for direct binding studies, the Abo preparation used in the NMR
screening was tested for their binding to PrPC on the surface of
HEK293 cells. The cells were stained by anti-Ab antibodies,
Phallodin (cytoskeleton stain) and DAPI (nuclei). Both synthetic
Ab1-42 oligomers as described above and recombinant Abo
produced by CHO 7PA2 cells were examined in the binding
studies to PrPC in the HEK293 cell model and both showed
similar level bindings (data not shown). However, Abo prepared
from synthetic Ab1-42 monomers displayed noticeable interfer-
ence in immunostaining in confocal and ICC assays due to
some large particles present which did not pose much problems
in NMR experiments. The recombinant Abo were obtained from
the supernatant aer harvest of the cells and debris removed.
They contain a heterogeneous population of monomers,
dimers, trimers, tetramers, higher state soluble oligomers and
other cellular proteins as previously reported by western blot-
ting. The recombinant Abo were therefore used in all cellular
assays (HEK cell binding assay and subsequent hiPSC func-
tional assays). The recombinant Abo were produced by CHO
7PA2 cells transfected with cDNA encoding APP751 containing
Val 717Phe familial AD mutation and quantied by ELISA.
When compared with the control (Fig. 6d, rst panel), Abo
were shown to be able to bind to PrPC on the cell surface of
HEK293 cells (Fig. 6d, second panel). The binding of Abo–PrPC
can be signicantly blocked by anti-prion antibody 6D11, raised
against the epitope containing amino acids 93–109 of PrPC. This
antibody was reported to block the interaction between Abo and
PrPC.61,63 Its inhibitory effect was conrmed in our HEK293
direct binding assay (Fig. 6d, third panel). The inhibition ofChem. Sci., 2021, 12, 3768–3785 | 3777

































































































View Article Online6D11 on the binding of Abo to PrPC on the cell surface was
further reduced by PLC treatment as previously reported64 (Fig.
6d, forth panel). The binding of Abo on endogenous PrPC on
wild type HEK293 cells and inhibitory effect of known inhibi-
tors, 6D11 and PLC are quantied (Fig. 6e).
The ability of our hit compounds to disrupt the Abo–PrPC
interaction in HEK293 cells was assessed using a live-cell
binding assay. The binding was visualised and quantiedFig. 6 Assessment of PrPC expression level and Abo binding to PrPC and in
in relevant neural cell lines; (b) HEK293 staining with DAPI (left), PrPC antib
(d) from left to right: control HEK293 cells, HEK293 cells treated with Abo
PrPC antibody 6D11, HEK293 cells treated with Abo and PLC. Cells are st
quantification of Abo binding to PrPC and inhibition of 6D11 and PLC;
absence of each compounds by immunofluorescence. Values expressed
comparison with control groups and *p < 0.05, **p < 0.01, ***p < 0.001,
way ANOVA and Tukey's post-hoc test.
3778 | Chem. Sci., 2021, 12, 3768–3785using immunocytochemistry (ICC). Prior to the binding assay,
the cytotoxicity of selected compounds was assessed using MTT
assay on HEK293 cells. The viabilities of all compounds are
excellent with LD50 > 50 mM except compound PBCHM57487213
having LD50 at around 27 mM (ESI Fig. 1†).
In the binding assay, HEK293 cells were incubated with Abo
at a concentration of 1000 pg mL1 for 2 hours. The culture
medium was then removed and the cells were washed. This washibition of hit compounds. (a) Expression of a selection of neural genes
ody 8H4 (right); (c) quantification of PrPC in HEK293 by flow cytometry;
at 1000 pg mL1 for 2 hours, HEK293 cells treated with Abo and anti-
ained with anti Ab antibody (green), Phalloidin (red) and DAPI (blue); (e)
(f) percentage of binding of Abo to PrPC on HEK293 in presence and
as mean  SD (n $ 3), statistical significance indicated by #p < 0.05 in
****p < 0.0001 in comparison with Abo treated group, following one-
© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article Onlinefollowed by adding the tested compound in fresh medium at
a nal concentration of 10 mM. The cells were then le for 1
hour prior to ICC analysis. The percentage of the binding of Abo
in presence and absence of the tested compound is presented in
(Fig. 6f). Compounds ZINC00120199 and PBCHM4680099 both
showed very little inhibitory effects upon the Abo–PrPC binding
while the other 4 compounds all showed clear and statisticallyFig. 7 pFyn deactivation and kinase activity assay using NPC. (a) Immu
progenitor cell marker (red) and anti-prion (green), the nucleus was sta
expression in NPC cells by flow cytometry. (c) Quantification of PRNP an
plan; (e) confirmation of Abo induced pFYN activation using natural Abo a
PP1 a well-known pFyn inhibitor using immunostaining; (f) quantificatio
inhibition of Abo binders in pFYN activation caused by Abo; values express
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, following one-way
© 2021 The Author(s). Published by the Royal Society of Chemistrysignicant inhibition effects. These two compounds seem to
have relatively small molecular weight and fewer rotatable
bonds.
The Abo binders inhibit hyperphosphorylation of Fyn (pFyn)
in hiPSC derived neuroprogenitor cell (NPC). For further func-
tional validation of the hit compounds, appropriate cellular
models of biological relevance needed to be developed. HEK293nofluorescence double staining of NPC for nestin a classical neural
ined by DAPI (blue) and overlays; (b) confirmation of nestin and PrPC
d FYN gene expression in NPC cells by qPCR; (d) compound treatment
nd inhibition of the pFYN activation by anti-prion antibody (6D11), and
n of the level of inhibition of pFYN activation with 6D11 and PP1; (g)
ed as mean SD (n$ 3), statistical significance indicated by #p < 0.05,
ANOVA and Tukey's post-hoc test.
Chem. Sci., 2021, 12, 3768–3785 | 3779

































































































View Article Onlineis not appropriate because it is not of neural origin, SH-SY5Y
cell lines are human neuronal cell lines, but they don't
express all AD signalling pathways. The best choice would then
be the iCells neurons however, due to their cost they were not
viable for this work. Thus, we developed our own neuronal stem
cells models using human iPSC cells. These human neuronal
stem cell models are more genetically and functionally relevant
to study human neurons than those of animal origins.65
To assess the effects of hit compounds on pFyn activity, iPSC-
derived NPCs from a health control individual (Cell line MIFF1
https://web.expasy.org/cellosaurus/CVCL_1E69) in under 3
weeks (much shorter than the time it takes to produce natural
neurons) and express all essential biomarkers as mature
neurons. The expression of the NPC marker, Nestin, and Abo
binding partner, PrPC, and PRNP and FYN genes were
conrmed using immunostaining (Fig. 7a), ow cytometry
(Fig. 7b) and qPCR (Fig. 7c).
The Abo binders were tested using the same protocol and
results are shown (Fig. 7d). The screening protocol was devel-
oped using commercial anti-prion antibody, 6D11 and a well-
known pFYN inhibitor PP1. 6D11 is a monoclonal anti-mouse
IgG against epitope 93–109 on PrPC sequence. Recently, this
antibody has been found to improve the cognitive decits in an
Alzheimer's disease mice model63,66,67 and prevent the binding
of Abo to PrPC causing Fyn alteration and Tau hyper-
phosphorylation.68 We used 6D11 as a positive control for
developing the Fyn functional assay. PP1 is a cell-permeable
pyrazolopyrimidine compound that is shown to inhibit Src
family tyrosine kinases Lck, Fyn, Hck, and Src (IC50 ¼ 5, 6, 20,
and 170 nM, respectively) in in vitro kinase assays with an
application as an anticancer agent.69–71
Both 6D11 and PP1 were used to treat 3 day old NPC in
culture for 1 hour prior to Abo treatment. The cells were har-
vested for immunouorescence analysis 15 minutes aer the
treatment. When compared to the untreated control cells, Abo
caused hyperphosphorylation of Fyn, hence the activation of the
Fyn kinase. Both 6D11 and PP1 signicantly inhibit the activa-
tion of pFyn (Fig. 7e & f). PP1 was chosen as a positive control
Abo binder screening in our pFyn assay as it is a small molecule
inhibitor (Fig. 7g). While 5 out of the 6 compounds reduced the
Fyn hyperphosphorylation triggered by Abo, compound
PBCHM9815618 and PBCHM57487213 produced the most
profound effects.
We were specically interested in pFyn because it is widely
expressed in the brain, it is abundant in neurons and it plays an
important role in regulating cell proliferation and differentia-
tion during the development of the CNS.72 It is also involved in
signal transduction pathways that regulate survival metabolism
and neuronal migration.73 We focused our studies on the effects
of the compounds upon the reduction of the elevated level of
pFyn (hyperphosphorylation) because any compound that
reduces the pFyn level below the basal levels could be delete-
rious for the homeostasis of the cells and their mode-of-actions
are unrelated to the activation of Fyn caused by the Abo.
The Abo binders reduce the production of phosphorylated
Tau (pTau) in mature cortical neurons. As pTau is the key
component in Tau tangles produced in the neurons in the brain3780 | Chem. Sci., 2021, 12, 3768–3785of patients as the result of AD, it is thus a characteristic
biomarker. Therefore, in order to test the effects of Abo binders
upon pTau production, mature cortical neurons generated from
iPSC from a healthy individual (MIFF1) were obtained aer 75
days as previously reported protocol illustrated in Fig. 8a. Key
biomarkers for each cell type (DAPI) was used as a general
marker for nuclei; SSEA4, Oct4 for iPSC (data not shown); Nestin
and PAX6 for NPC (data not shown); b-tubulin III for young
neurons and mGlu5 for mature cortical neuron were used to
guide the differentiation at each stage prior to full
characterizations.
Cells were stained for major protein biomarkers in sig-
nalling pathways related to AD development in neurons
including general neuronal markers such as b-tubulin 3
(btub-III) and MAP2, specic glutamatergic markers for
cortical neurons such as N-methyl D-aspartate receptor
subtype 2B (NMDAR2B or NR2B) and mGluR5, PrPC, synaptic
markers such as synaptophysin (SYP) and PSD-95 (post-
synaptic density protein 95) (Fig. 8b). Both NPC and neurons
showed positive staining for those markers. The physiolog-
ical functions of these mature neurons were characterized
using electrophysiological functional parameters, i.e. action
potential (Fig. 8c top) and voltage-gated potassium and
sodium ion channel current (Fig. 8c bottom). The data clearly
show that iPSCs have been successfully differentiated into
mature cortical neurons over an extended period of time and
function as normal neurons physiologically. The treatment
regime for compounds and Abo is illustrated in Fig. 8d. Upon
the treatment of Abo binders, signicant pTau deposits were
clearly seen while the amount of pTau in the untreated
control is negligible (Fig. 8e).
Briey, the iPSC derived nature neurons were passaged and
grown for 15 days in B27/BDNF medium, then treated by
a mixture of recombinant Abo at 500 nM and tested compounds
at 5 and 10 mM. The inhibitory effects of the 6 hit Abo binders
upon the pTau production induced by Abo can be clearly seen in
Fig. 8f. Amongst all Abo binders, ZINC0011291995 is the
weakest inhibitor, PBCHM4680099 somewhat displays an
inverse dose–response trend. Clearer dose-responses effects can
be seen with compounds PBCHM120765 and CHEMBL1673279
although PBCHM120765 seems to be a slightly stronger inhib-
itor. Inhibitory effects of compounds PBCHN81560982 and
PBCHM57487213 stayed the same which is similar to that
PBCHM120765 possesses at 10 mM concentration.
Positive outcomes from each assay can be clearly seen from
individual cell-based assay. In HEK293 binding assay, 4 out of 6
compounds (CHEMBL1673279, PBCHM57487213,
PBCHM120765, and PBCHM81560982) showed clear effects in
disrupting Abo–PrPC binding through specic binding to Abo
although their direct binding to PrPC can not be excluded.
Compounds, PBCHM57487213 and PBCHM120765 showed
noticeable effect in reducing the elevated pFyn level in NPC
triggered by Abo treatment while inhibitory effects of other
compounds are observed but not signicant. Inhibitory effects
on pTau production in mature cortical neurons can be seen
with most of the compounds, but statically signicant© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 8 pTau assay using mature cortical neurons derived from iPSC. (a) Protocol for differentiating iPSC into neuroprogenitor cells and then
mature cortical neurons; (b) characterisation of iPSC derived nature cortical neurons by immunostaining of neuronal markers (b-tubulin III, Fyn,
NR2B, PrPC, mGluR5, PSD95, SYN andMAP2); (c) electrophysiological characterization of iPSC-derived mature cortical neurons. Action potential
(top) K+–Na+ ion channel current (bottom) for mature cortical neurons; (d) treatment protocol for Abo binders for their inhibitory effects on pTau
production usingmature cortical neurons; (e) pTau production induced by Abo; (f) inhibition of pTau by 6 Abo binders. Values expressed as mean
 SD (n $ 3), statistical significance indicated by #p < 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, following one-way ANOVA and
Tukey's post-hoc test.
© 2021 The Author(s). Published by the Royal Society of Chemistry Chem. Sci., 2021, 12, 3768–3785 | 3781


































































































Table 4 Ranking of 6 hit compounds cross all three functional assays

































































































View Article Onlineinhibitory effects were observed with compounds
CHEMBL1673279, PBCHM57487213, PBCHM120765, and
PBCHM81560982.
When the data from NMR and biological assays looks a little
dispersed which make cross-board comparison a little difficult.
In order to give a holistic assessment of the data, activities of all
6 compound under each of the 3 biological experiments were
categorised as such 0–10 (red), 10–20 (orange/yellow) and >20
(green). Compounds with cross-board high activities (all >20, in
green) were selected as lead compounds (Table 4). The other
approach for lead compounds shortlisting was to use results
from each one of the 5 assays (19F NMR, STD NMR plus 3 bio-
logical assays) which was arbitrarily ranked with highest activity
assigned 6 and lowest one assigned as 1 in a descend order. The
combined rank was produced. The one with the highest value
was selected as lead compounds (data not shown). Both
approaches yielded the same shortlist of lead compounds two
nal leads (PBCHM57487213 and PBCHM81560982) were
selected aer assessment of overall data although compound
PBCHM120765 sits on the board line.
Both lead compounds came from the PUBCHEM collection.
Both are uorine-containing small molecules. Compound
PBCHM57487213 is a chiral amino alcohol with 2 stereogenic
centres. It can be synthesised by the ring opening of appropri-
ately protected epoxide with correct stereo congurations using
a triuoromethyl benzylamine. This compound was patented
(US20120053200A1) as a BACE-2 inhibitor which is potential
drug target associated with both Alzheimer's diseases and3782 | Chem. Sci., 2021, 12, 3768–3785diabetes. Compound PBCHM81560982 is a simple acylated
amino benzoic acid and its biological activity of has not been
reported in any literature so far. Both lead compounds are drug-
like, obeying Lipinski's and Veber's rules. They can be further
optimised and developed into anti-AD drugs. As both
compounds have relatively lowmolecular weight and have some
fragment features, an obvious strategy for optimisations could
simply be merge these two compounds into one molecule to see
if a synergistic activity can be achieved.
These lead structures connect three pillars of Alzheimer's
diseases, i.e. prion, Ab and Tau pathways. Abo binding is a key
feature in Ab pathway, Abo–PrPC inhibition connects the Ab
pathway with prion pathway while pTau are key components in
Tau pathways and can be triggered by Abo and linked with PrPC
and the activation of Fyn.68,74 The experiment was designed to
test the effects of the hit compounds on the downstream
pathways.Conclusions
In this work, we sought to identify compounds which bind to
soluble Ab1-42 oligomers (Abo) using a suite of computational,
biophysical and biological methods. Soluble Abo are the toxic
subunits of Alzheimer's disease (AD). A growing body of litera-
ture has indicated that the cellular prion protein (PrPC) acts as
a receptor for Abo in AD and connects the Ab pathway and the
Tau pathway. It is expected that Abo binders that disrupt the
Abo and PrPC interaction may have effects on downstream© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article Onlinesignalling such as Fyn and Tau activities, therefore, possess
polypharmacological activities.
Solving the crystal structure of the major disease-causing
amyloid peptide, Ab1-42 and its oligomers, has proven to be
extremely challenging. Most structural information came from
solution or solid-state NMR studies. There is neither X-ray
crystal structure of Ab1-42 in the oligomeric form nor ligand
co-crystallised structures being solved so far, although there are
several structures of Ab brils (PDB codes: 2MXU, 2LNQ, 6OC9,
6Y1A). This has made structure-based ligand design or high
throughput screening unattainable. Therefore, a ligand-based
computational approach was developed to rationalize the
selection of potential candidate molecules for biophysical and
biochemical screening.
With 19F NMR as a primary screening tool in mind,
a computational method was employed that uses fragments of
known binders to amyloidal proteins to search for compounds
containing similar substructures and at least one F-atom in our
compiled database of compounds which are in the public
domain as well as available in Lilly's internal inventory. 614
soluble compounds out of 971 virtual hits were screened in 91
sub-libraries in 19F NMR primary screening and 27 compounds
were identied as the Abo binders. Further validation in indi-
vidual experiments by 19F NMR against Abo and against
a scrambled Ab-peptide to eliminate false positives and non-
specic binding generated 8 conrmed hits. Further hit
expansion on these 8 initial hits produced 36 analogues from
which 6 more hits were obtained. This gave a total of 14 hit
binders which were taken into the STD NMR experiment.
The STD experiment on the 14 initial hit compounds resul-
ted in 9 conrmed hits. The hot spots which are involved in the
binding of the hit compounds to Abo were mapped out during
the STD experiments. Semi-quantitative dose–response curve
gave KD value at low micromolar levels. The combinations of
various experiments using computer-aided design tools, 19F and
STD NMR provided the most stringent assessment of potential
binders to Abo. 6 out 9 hit binders (CHEMBL1673279,
PBCHM4680099, PBCHM57487213, ZINC00120199,
PBCHM120765, and PBCHM81560982) were taken forward in
the biological evaluation studies.
The compounds were tested in three cellular assays, one
measuring Abo–PrPC binding using a HEK293 cell line and the
other two assessing changes in the levels of other key AD protein
biomarkers including Fyn and Tau using NPC and neurons
derived from iPSC. 4 out of 6 compounds (CHEMBL1673279,
PBCHM57487213, PBCHM120765, and PBCHM81560982)
showed good anti-oligmeropathy effects in disrupting Abo–PrPC
binding although these compounds did not show direct
binding to PrPC. The polypharmacological effects of the hit
compounds on pFyn and pTau were evaluated in hiPSC derived
NPC and cortical neuron models. Compounds
PBCHM57487213 and PBCHM120765 showed noticeable effect
in reducing the elevated pFyn level in NPC triggered by Abo
treatment while inhibitory effects of other compounds were
observed but not statistically signicantly. Inhibitory effects on
pTau production in mature cortical neurons can be seen with
most of the compounds, but statistically signicant inhibitory© 2021 The Author(s). Published by the Royal Society of Chemistryeffects were observed with compounds CHEMBL1673279,
PBCHM57487213, PBCHM120765, and PBCHM81560982.
The two nal leads (PBCHM57487213 and PBCHM81560982)
were selected aer assessment of overall data. The work
successfully demonstrated a combined computational,
biophysical and biochemical effort in AD drug discovery. The
computational method provides a plausible hit rationale for
suggesting compounds for NMR screening; 19F and STD NMR
have been shown to be effective tools for validating the
compounds suggested by the computational design. Cellular
models provided sound biochemical and functional validation
of Abo binders in the anti-oligmeropathy and poly-
pharmacology context. The rate has been improved from 1.3%
in initial 19F NMR screening to 17% in hit expansion, to 62% in
STD NMR. A hit rate of 50% was achieved aer the biochemical
and functional assays. The lead structures that were discovered,
connect 3 pillars in Alzheimer's disease pathology, i.e. prion, Ab
and Tau pathways. They showed polypharmacological effects on
3 different pathways through specic binding to Abo, i.e. anti-
oligomeropathy mechanism. These compounds are drug-like
and can be further optimised to produce useful AD thera-
peutic drugs.Conflicts of interest
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